New injection tested for Tough-to-Treat Muscle-Weakening disease
Disease control
Terminated
This early study tested a new injection called HN2301 in a small group of adults with myasthenia gravis that did not respond well to standard treatments. The main goal was to check if the treatment was safe and tolerable. Researchers also looked for early signs that it might help…
Phase: NA • Sponsor: Shenzhen MagicRNA Biotechnology Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC